Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Irinotecan is a topoisomerase I inhibitor that has been approved for use as a first- and second-line treatment for colorectal cancer. The response to irinotecan is variable, possibly because of interindividual variation in the expression of the enzymes that metabolize irinotecan, including cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin metabolism and midazolam clearance, and the metabolism of irinotecan and its active metabolite SN-38. METHODS: Of the 30 white cancer patients, 27 received at least two treatments with irinotecan administered as one 90-minute infusion (dose, 600 mg) with 3 weeks between treatments, and three received only one treatment. Before the first and second treatments, patients underwent an erythromycin breath test and a midazolam clearance test as phenotyping probes for CYP3A4. Erythromycin metabolism was assessed as the area under the curve for the flux of radioactivity in exhaled CO2 within 40 minutes after administration of [N-methyl-14C]erythromycin. Midazolam and irinotecan were measured by high-performance liquid chromatography. Genomic DNA was isolated from blood and screened for genetic variants in CYP3A4 and UGT1A1. All statistical tests were two-sided. RESULTS: CYP3A4 activity varied sevenfold (range = 0.223%-1.53% of dose) among patients, whereas midazolam clearance varied fourfold (range = 262-1012 mL/min), although intraindividual variation was small. Erythromycin metabolism was not statistically significantly associated with irinotecan clearance (P = .090), whereas midazolam clearance was highly correlated with irinotecan clearance (r = .745, P<.001). In addition, the presence of a UGT1A1 variant with a (TA)7 repeat in the promoter (UGT1A1*28) was associated with increased exposure to SN-38 (435 ng x h/mL, 95% confidence interval [CI] = 339 to 531 ng x h/mL in patients who are homozygous for wild-type UGT1A1; 631 ng x h/mL, 95% CI = 499 to 762 ng . h/mL in heterozygous patients; and 1343 ng x h/mL, 95% CI = 0 to 4181 ng x h/mL in patients who are homozygous for UGT1A1*28) (P = .006). CONCLUSION: CYP3A4 phenotype, as assessed by midazolam clearance, is statistically significantly associated with irinotecan pharmacokinetics. Evaluation of midazolam clearance combined with UGT1A1*28 genotyping may assist with optimization of irinotecan chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Self-citation
Cited by
Cytochrome P450 pharmacogenetics and cancer
Rodriguez-Antona, C., & Ingelman-Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 575
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“The importance of CYP3A4 and CYP3A5 in irinotecan metabolism is underlined by the strong correlation between irinotecan and midazolam clearance [51].”
BackgroundSelf-citationCigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
van der Bol, J. M., Mathijssen, R. H. J., Loos, W. J., Friberg, L. E., van Schaik, R. H. N., de Jonge, M. J. A., Planting, A. S. T., Verweij, J., Sparreboom, A., & de Jong, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6115 · Cited by 128
Self-citationRepurposing antifungal drugs for cancer therapy
Weng, N., Zhang, Z., Tan, Y., Zhang, X., Wei, X., & Zhu, Q. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.018 · Cited by 60
Metadata
- Authors
- Mathijssen, R. H. J., de Jong, F. A., van Schaik, R. H. N., Lepper, E. R., Friberg, L. E., Rietveld, T., de Bruijn, P., Graveland, W. J., Figg, W. D., Verweij, J., & Sparreboom, A.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-02
- Volume
- 96
- Issue
- 21
- Pages
- 1585-1592
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2031995371
- Cited by
- 119
- References
- 2
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. https://app.cochat.ai/papers/10.1093/jnci/djh298
- The paper
- Mathijssen, R. H. J., de Jong, F. A., van Schaik, R. H. N., Lepper, E. R., Friberg, L. E., Rietveld, T., de Bruijn, P., Graveland, W. J., Figg, W. D., Verweij, J., & Sparreboom, A. (2004). Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djh298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.